Iteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

iTeos Therapeutics

07/08/2025 20:29

Iteos Therapeutics Inc ITOS.OQ reported a quarterly adjusted loss of $1.43​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -18 cents.  The mean expectation of five analysts for the quarter was for a loss of $1.01 per share. Wall Street expected results to range from $-1.56 to -82 cents per share.

Reported revenue was zero​; analysts expected zero.

Iteos Therapeutics Inc's reported EPS for the quarter was a loss of $1.81​.

The company reported a quarterly loss of $78.73 million.

Iteos Therapeutics Inc shares had risen by 1.4% this quarter and gained 31.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 10.6% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Iteos Therapeutics Inc is $10.10, about 0.1% below its last closing price of $10.11

This summary was machine generated from LSEG data August 7 at 07:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.01
-1.43
Missed
Mar. 31 2025
-0.95
-0.80
Beat
Dec. 31 2024
-1.06
-1.03
Beat
Sep. 30 2024
-0.89
-1.05
Missed